ArticleMolecular cancer2026
Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe success of novel antibody-drug conjugates, such as trastuzumab deruxtecan (T-DXd) and disitamab vedotin (RC48), has been pivotal in rendering “HER-2-low” gastric cancer (GC) a therapeutically targetable entity, expanding the population benefiting from anti-HER2 therapy by 2-3-fold. This advancement underscores the imperative to redefine and subclassify HER-2 status in GC. In this study, we innovatively proposed a four-tiered HER-2 classification standard for GC and, for the first time, conducted comparative analyses at the spatial single-cell multi-omics level across these four subgroups.
methodsHER-2 status was recategorized into absent (immunohistochemistry (IHC) 0+, HER2_N), low (IHC 1+, HER2_L), moderate (IHC 2+/fluorescence in situ hybridization (FISH)-, HER2_M), and high (IHC 2+/FISH + or IHC 3+, HER2_H) groups. Primary tumor samples from 427 GC patients were collected and analyzed using Xenium5K in situ single-cell spatial transcriptomics (n = 153) and multiplex immunofluorescence (n = 427) detection base on tissue microassays.
resultsThe proportion of samples that classified as HER2_N, HER2_L, HER2_M, and HER2_H was 43.13%, 22.88%, 11.11%, and 22.88%, respectively. Spatial HER-2 heterogeneous expression existed in 74.42% of HER-2 expressing GC and in 40.0% of HER2_H cases, which correlated with an unfavorable response to combined HER-2-targeted and immunotherapy and poor prognosis. In HER2_H group, lower infiltrates of exhausted T cells and regulatory T cells (Treg), higher cytotoxic activity of T cells, and enriched T cell-B cell niches were discovered, presenting a favorable tumor microenvironment that may benefit from immunotherapy. In HER2_M population, significantly higher CTLA4 + Treg infiltration, and their strengthened interactions with other cells via the CD80/CD86-CTLA4 axis were highlighted. HER2_L group exhibited increased infiltrates of SOX2-OT + mesenchymal cells and TGF-β-driven stromal-tumor cellular interactions. Moreover, HER2_N group presented a higher prevalence of diffuse and mixed histology, enriched endothelial cell-fibroblast-myeloid-derived suppressor cell niches, and augmented angiogenic activity.
conclusionDifferences in clinicopathologic, molecular, and immunological underpinnings were underscored across GC with differential HER-2 expression status, providing a rationale for a novel quaternary HER-2 classification system and the development of stratified therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.